Antisynthetase Syndrome

Slide 1 · Antisynthetasesyndrome

Autoantibodies, multisystem manifestations, and muscle pathology

Pathology and clinicopathologic interpretation

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning outcomes

Define the syndrome using its characteristic antisynthetase autoantibody family.

Recognize the muscle–lung–joint pattern and the distribution of characteristic skin changes.

Interpret perifascicular and scattered patterns of myofiber injury.

Distinguish the syndrome from dermatomyositis, immune-mediated necrotizing myopathy, and sporadic inclusion body myositis.

Slide 3 · A serologically defined multisystem disorder

Serum antibodies directed against aminoacyl-transfer RNA synthetases define the disease.

Muscle

Myositis; Weakness; Myalgias

Lung

Interstitial lung disease

Joints

Arthritis; Sometimes arthralgias

The label is not restricted to muscle: The syndrome encompasses several tissues.

Slide 4 · Where antisynthetase syndrome fits

Idiopathic inflammatory myopathies

Dermatomyositis

Antisynthetase syndrome

Immune-mediated necrotizing myopathy

Sporadic inclusion body myositis

Overlap myositis

Polymyositis

Modern classification separates disorders that were previously grouped under broad inflammatory-myopathy labels.

Slide 5 · Why the old “polymyositis” label became smaller

Historical category

Polymyositis was part of a traditional three-part scheme.

Clinicopathologic reassessment

Antibodies and clinical phenotypes reveal distinct entities.

Current classification

Many former cases map to ASS, IMNM, or sIBM.

A broad historical diagnosis is not an endpoint when a definable entity can be recognized.

Slide 6 · Three dimensions of disease recognition

Serology

Antisynthetase antibody family

Clinical involvement

Myositis · ILD · arthritis; Additional findings

Morphology

Perifascicular injury or scattered necrosis

Interpret the dimensions together; One biopsy pattern is not a substitute for the syndrome definition.

Slide 7 · Muscle fascicle and the perifascicular zone

Schematic muscle fascicle

Boundary

Blue contour: Edge of fascicle

Small fibers

Reduced diameter = atrophy

Marked × fibers

Necrosis shown symbolically

A fascicle contains many myofibers. “Perifascicular” refers to fibers near the outer edge.

Slide 8 · Perifascicular is a location, not a diagnosis

Anatomic descriptor

• Atrophy or necrosis preferentially involves fibers near the fascicular edge.

• The term describes topography of injury.

Interpretive limitation

• Both antisynthetase myositis and dermatomyositis may show this distribution.

• Combine morphology with serology and clinical features.

Slide 9 · Primary myopathic injury is a myofiber process

Muscle fiber injury

Segmental degeneration can occur within a multinucleated myofiber.

Necrosis

Damaged muscle components are lost.

Repair attempt

Macrophages clear debris; Regeneration may follow.

Source contrasts primary myopathic changes with patterns caused by loss of innervation.

Slide 10 · Why serum CK rises after muscle damage

Sarcolemmal / myofiber injury

Intracellular muscle contents become accessible to blood.

Enzyme escape

Creatine kinase is released.

Laboratory signal

Elevated CK supports muscle damage, not a unique myositis subtype.

CK is a marker of damage, not proof of one named immune myopathy.

Slide 11 · Myophagocytosis removes injured sarcomeres

Degenerated segment

Sarcomeres and myofiber components are disrupted.

Macrophage response

Debris is engulfed: Myophagocytosis.

Repair bed

Clearance permits a regeneration response.

Slide 12 · Satellite-cell fusion supports regeneration

Activated satellite cells

Muscle regenerative progenitors respond to damage.

Fusion

Cells fuse with the damaged myofiber.

Restoration

New sarcomeres can restore fiber continuity.

This repair sequence is from general myopathic changes, not asserted as a specific antisynthetase mechanism.

Slide 13 · The appearance of a regenerating myofiber

Regenerating fiber

• Basophilic cytoplasm due to high RNA content.

• Enlarged nucleoli and nuclei that can lie internally.

Normal mature fiber

• Less cytoplasmic basophilia.

• Nuclei usually reside beneath the sarcolemma.

Slide 14 · When regeneration cannot match injury

Repeated damage

Degeneration continues over time.

Insufficient replacement

Regeneration fails to keep pace.

Chronic remodeling

Fiber dropout, endomysial fibrosis, fatty replacement.

Generic chronic myopathy consequence; Not reported as a frequency in ASS.

Slide 15 · The autoantibody family is central to the name

All listed antibody specificities target the aminoacyl-tRNA synthetase family.

Anti-Jo-1

Anti-PL-7

Anti-PL-12

Anti-EJ

Anti-Ha

The source identifies these examples but does not establish a subtype frequency distribution.

Slide 16 · Anti-Jo-1 is the prototypical association

Anti-Jo-1

It as the most common and prototypical antisynthetase association.

Its name is one member of a broader antibody-defined family.

Do not equate “antisynthetase syndrome” with anti-Jo-1 alone.

Slide 17 · Non–Jo-1 examples are part of the same disease

Several other antisynthetase specificities occur.

Anti-PL-7

Anti-PL-12

Anti-EJ

Anti-Ha

No prevalence hierarchy among these listed non-Jo-1 antibodies is supplied in the assigned source.

Slide 18 · An autoantibody association is not a complete mechanism

What the textbook establishes

• Serum anti–aminoacyl-tRNA synthetase antibodies define the syndrome.

• Muscle and other tissues are affected.

What it does not establish

• An antibody-by-antibody direct injury pathway.

• The exact mechanism of each organ lesion.

Do not infer direct pathogenic causation from nomenclature alone.

Slide 19 · The core clinical triad

Myositis

Muscle weakness and myalgia

Interstitial lung disease

Pulmonary involvement

Arthritis

Inflammatory joint involvement

Named manifestations may coexist; The source does not mandate all three simultaneously in every patient.

Slide 20 · Muscle manifestations are more than one symptom

Weakness

• Loss of muscle force is a functional manifestation.

• It reflects clinically relevant myositis.

Myalgia

• Muscle pain is a symptomatic manifestation.

• Weakness and pain are related but not interchangeable clinical observations.

Slide 21 · Myositis links symptoms to structural injury

Clinical myositis

Weakness and myalgias

Muscle injury

Atrophy and/or necrosis of fibers

Pathology readout

Pattern of injury helps refine the differential

The diagram links manifestations and pathology without specifying an unverified pathogenic pathway.

Slide 22 · Interstitial lung disease extends disease beyond muscle

Interstitial lung disease

One of the principal manifestations in the Robbins description.

Its presence in a patient with myositis changes the diagnostic pattern.

It is part of the core muscle–lung–joint phenotype.

Slide 23 · Arthritis and arthralgia are not synonyms

Arthritis

• A core manifestation listed for antisynthetase syndrome.

• Denotes an inflammatory joint disease.

Arthralgia

• A less common associated feature account.

• Denotes joint pain; Inflammatory arthritis should not be inferred from pain alone.

Slide 24 · Other manifestations expand the clinical picture

Fever

Listed as an additional, less common feature.

Raynaud phenomenon

An additional associated vascular symptom complex.

Cutaneous change

Mechanic’s hands are the specific skin morphology described.

The source describes these as rare or other manifestations, not part of a formal universal checklist.

Slide 25 · “Mechanic’s hands” have characteristic topography

Described skin change: Hyperkeratotic, fissuring patches

Fingers

Radial aspects of the fingers: Surfaces on the thumb-facing side.

Thumb

Ulnar aspect of the thumb: Surface facing the index finger.

Anatomic distribution; Not a patient photograph

Slide 26 · Mechanic’s hands versus the classic DM rash

Dimension

Antisynthetase syndrome

Dermatomyositis

Skin descriptor

Mechanic’s hands

Heliotrope rash; Gottron papules

Site emphasized

Radial finger edges; Ulnar thumb edge

Eyelids; Knuckles, elbows, knees

Interpretive value

Supports a multisystem antibody-defined syndrome

Characteristic dermatomyositis manifestations

Slide 27 · Clinical recognition is pattern-based

Recognize multi-organ clues

Myositis, ILD, arthritis; Skin/vascular features

Identify antibodies

Anti–aminoacyl-tRNA synthetase specificity

Correlate muscle morphology

Perifascicular or scattered injury; Assess mimics

Educational reasoning pathway, not a validated diagnostic classification criterion.

Slide 28 · Biopsy can show more than one injury distribution

Perifascicular atrophy

Smaller fibers at fascicle margins

Perifascicular necrosis

Necrotic fibers preferentially near margins

Randomly distributed necrosis

Damaged fibers without edge restriction

All patterns appear in the Robbins description of antisynthetase myositis.

Slide 29 · Perifascicular atrophy

Schematic muscle fascicle

Boundary

Blue contour: Edge of fascicle

Small fibers

Reduced diameter = atrophy

Marked × fibers

Necrosis shown symbolically

Schematic only: Smaller peripheral myofibers reflect perifascicular atrophy, not a specific diagnosis.

Slide 30 · Perifascicular necrosis

×

×

×

×

×

×

×

×

×

×

×

×

×

×

×

×

Schematic muscle fascicle

Boundary

Blue contour: Edge of fascicle

Small fibers

Reduced diameter = atrophy

Marked × fibers

Necrosis shown symbolically

Schematic only: Crosses mark damaged fibers concentrated at fascicle edges.

Slide 31 · An edge-weighted injury pattern

What the biopsy shows

• Fiber atrophy and/or necrosis emphasizes the perifascicular compartment.

• The descriptor is based on position within a fascicle.

What the biopsy cannot decide alone

• The same broad topography may occur in dermatomyositis.

• Serology and organ involvement remain relevant.

Slide 32 · Scattered necrosis is also compatible with the syndrome

×

×

×

×

×

×

×

×

×

×

×

×

Schematic muscle fascicle

Boundary

Blue contour: Edge of fascicle

Small fibers

Reduced diameter = atrophy

Marked × fibers

Necrosis shown symbolically

Schematic only: The source explicitly allows cases with more randomly distributed necrotic myofibers.

Slide 33 · Two injury patterns should not be conflated

Dimension

Perifascicular pattern

Scattered pattern

Topology

Edge of fascicle emphasized

No preferential edge concentration

Primary finding

Atrophy and/or necrosis

Necrotic myofibers

Clinical significance

Can mimic dermatomyositis

Broadens spectrum of ASS muscle pathology

Slide 34 · Perifascicular atrophy is a shared histologic clue

Antisynthetase-associated myositis

• May show perifascicular atrophy and necrosis.

• Other biopsies show randomly distributed necrosis.

Dermatomyositis

• Classic biopsy feature is perifascicular atrophy.

• Additional vascular, interferon-related findings are described.

Slide 35 · Dermatomyositis: The clinical comparator

Weakness

Usually subacute, symmetric, proximal.

Skin

Heliotrope rash and Gottron papules are characteristic.

Systemic features

Variable antibody-linked phenotypes are described.

Slide 36 · Dermatomyositis: The classic perifascicular lesion

Schematic muscle fascicle

Boundary

Blue contour: Edge of fascicle

Small fibers

Reduced diameter = atrophy

Marked × fibers

Necrosis shown symbolically

Schematic pattern: Perifascicular atrophy is classical for dermatomyositis but not exclusive to it.

Slide 37 · Dermatomyositis has a strong interferon signature

Type I IFN pathway activation

A consistent feature account.

MxA overexpression

Histopathologic marker of IFN signaling.

Tissue interpretation

Supports dermatomyositis pattern in context.

The source notes that the exact role of interferon in disease pathogenesis is not established.

Slide 38 · Dermatomyositis also has vasculopathic pathology

Capillary abnormality

Telangiectasias and capillary dropout can occur.

Local effects

Muscle microvascular injury contributes to disease findings.

Morphology

Perifascicular atrophy; Occasionally microinfarcts.

Do not transplant the same mechanism to ASS without supporting evidence.

Slide 39 · Antisynthetase syndrome versus dermatomyositis

Dimension

Antisynthetase syndrome

Dermatomyositis

Defining association

Anti–aminoacyl-tRNA synthetase antibodies

Dermatomyositis-specific antibody profiles

Clinical emphasis

Myositis + ILD + arthritis

Myositis + characteristic skin eruptions

Perifascicular change

Atrophy and necrosis may occur

Classical perifascicular atrophy

Specific DM pathway

Not established by assigned ASS passage

Type I IFN/MxA association described

Slide 40 · The major inflammatory myopathy categories

Modern diagnostic separation

Antisynthetase syndrome

Dermatomyositis

Immune-mediated necrotizing myopathy

Sporadic inclusion body myositis

Overlap myositis

Residual polymyositis

Each phenotype is clarified by clinical and muscle-pathological patterns and/or associated antibodies.

Slide 41 · IMNM is defined by marked muscle injury

Prominent necrosis + high CK + rapidly progressive weakness

These form the defining pattern given by Robbins for immune-mediated necrotizing myopathy.

Systemic features typical of ASS are uncommon in IMNM.

The biopsy usually has scattered necrotic and regenerating fibers.

Slide 42 · Immune-mediated necrotizing myopathy: Antibodies

Antibodies associated with IMNM are distinct from the antisynthetase family.

Anti-SRP

Anti-HMGCR

SRP is a ribonucleoprotein; HMG-CoA reductase participates in cholesterol synthesis.

Slide 43 · Anti-SRP-associated IMNM may be particularly severe

Weakness

Often more severe disease.

Swallowing

Dysphagia occurs more often.

Heart

Cardiac involvement may develop.

Slide 44 · Anti-HMGCR and statin exposure

Association noted

• Anti-HMG-CoA reductase antibodies may be present following statin exposure.

• This is a recognized immune necrotizing myopathy subtype.

Important limitation

• Anti-HMGCR can also occur in statin-naïve patients.

• Statin exposure is not a necessary condition for this antibody association.

Slide 45 · IMNM biopsy: Necrosis with little inflammation

×

×

×

×

×

×

×

×

×

×

×

×

Schematic muscle fascicle

Boundary

Blue contour: Edge of fascicle

Small fibers

Reduced diameter = atrophy

Marked × fibers

Necrosis shown symbolically

Schematic only: Randomly distributed necrotic and regenerating fibers; Inflammatory infiltrates are sparse.

Slide 46 · Extramuscular manifestations distinguish many cases

Dimension

Antisynthetase syndrome

IMNM

Lung / joints

ILD and arthritis are principal components

Similar systemic findings occur in only a small subset

Muscle injury

Perifascicular or scattered necrosis

Prominent necrosis and regeneration

Typical serology

Anti-Jo-1 / PL-7 / PL-12 / EJ / Ha

Anti-SRP / anti-HMGCR

Slide 47 · Why necrosis alone cannot assign an antibody group

Overlap in tissue pattern

• Random necrosis may occur in antisynthetase myositis.

• IMNM shows marked random necrosis/regeneration.

Separating evidence

• Look for lung and joint phenotype.

• Interpret specific antibody association rather than the injury pattern alone.

Slide 48 · Sporadic inclusion body myositis: Typical age

Late-adulthood inflammatory myopathy

Usually affects individuals older than 50 years.

It as the most common inflammatory myopathy after age 65.

The course is characteristically slowly progressive.

Slide 49 · The weakness distribution points toward sIBM

Lower limb

• Quadriceps are often prominently affected.

• This can alter functions requiring knee extension.

Upper limb

• Distal upper-extremity muscles are often affected.

• Distribution differs from an exclusively proximal weakness pattern.

Functional consequences are explanatory interpretation, not exact source wording.

Slide 50 · SIBM: Dysphagia and comparatively mild CK elevation

Swallowing

Pharyngeal and esophageal involvement can cause dysphagia.

CK

Elevation usually comparatively mild.

Course

Smoldering, slowly progressive muscle disease.

Slide 51 · The biology of sIBM remains unsettled

Inflammatory features

• Shares characteristics with other idiopathic inflammatory myopathies.

• Autoantibodies to cN1A are described in many cases.

Degenerative features

• Abnormal protein aggregates occur in muscle cells.

• Whether inflammation is primary remains unresolved.

Slide 52 · SIBM often responds poorly to immunosuppression

Therapeutic-response pattern matters diagnostically

Generally poor responses to corticosteroids and other immunosuppressive agents.

This differs from the therapeutic framing of several other idiopathic inflammatory myopathies.

It reinforces the need to recognize sIBM as its own entity.

Slide 53 · Antisynthetase syndrome versus sIBM

Dimension

Antisynthetase syndrome

Sporadic IBM

Defining antibody

Antisynthetase family

CN1A associated in many, not presented as defining

Major systemic context

Myositis + ILD + arthritis

Typical quadriceps/distal upper-limb weakness

Course

Not quantified in excerpt

Slowly progressive, later-life

Histology discussed

Perifascicular or scattered necrosis

Protein aggregates; IBM pathology spectrum

Slide 54 · Polymyositis is now a narrower residual category

Older labeling

Classic inflammatory-myopathy triad included polymyositis.

Modern classification

Many cases are reassigned to more specific disorders.

Examples

ASS · IMNM · sporadic IBM

The source provides reclassification context, not a positive list of new polymyositis criteria.

Slide 55 · Integrating clinical, serologic and biopsy evidence

Clinical pattern

Muscle · interstitial lung · joints

Autoantibodies

Antisynthetase versus other myositis-associated families

Biopsy distribution

Perifascicular atrophy/necrosis or scattered necrosis

Educational synthesis, not an official diagnostic algorithm or formal criteria set.

Slide 56 · A morphology-first differential is provisional

Perifascicular injury?

Consider ASS and dermatomyositis.

Marked diffuse necrosis?

Consider IMNM; ASS remains possible.

Resolve with clinical/serologic context

Skin pattern, ILD, joint disease, specific antibody family

This is a teaching framework, not a validated decision rule; Morphology alone cannot establish diagnosis.

Slide 57 · Case 1 — muscle, lung and joint involvement

Illustrative teaching vignette

1. An adult develops weakness and myalgias.

2. Assessment finds interstitial lung disease and arthritis.

3. Serum anti-Jo-1 is reported.

Interpretation

Which unifying disease category is most strongly supported?

Antisynthetase syndrome: Characteristic antibody plus the muscle–lung–joint phenotype.

Vignette is illustrative; No individual patient or result is represented.

Slide 58 · Case 2 — necrosis outside the perifascicular zone

Illustrative teaching vignette

1. A patient has myositis with interstitial lung disease.

2. The biopsy shows necrotic myofibers scattered through fascicles.

3. An antisynthetase antibody is present.

Interpretation

Does scattered necrosis exclude antisynthetase syndrome?

No. Robbins explicitly describes randomly distributed necrotic fibers in some cases.

Vignette is illustrative; No individual patient or result is represented.

Slide 59 · Case 3 — rapidly progressive necrotizing disease

Illustrative teaching vignette

1. Weakness progresses rapidly and CK is high.

2. Biopsy shows abundant necrotic/regenerating fibers and few inflammatory cells.

3. Anti-SRP antibodies are present.

Interpretation

Which myositis subtype best fits?

Immune-mediated necrotizing myopathy with anti-SRP association.

Vignette is illustrative; No individual patient or result is represented.

Slide 60 · Case 4 — slowly progressive selective weakness

Illustrative teaching vignette

1. An older adult has years of progressive weakness.

2. Quadriceps and distal upper extremities are prominent.

3. CK elevation is relatively mild; Dysphagia is present.

Interpretation

Which inflammatory myopathy pattern is most typical?

Sporadic inclusion body myositis.

Vignette is illustrative; No individual patient or result is represented.

Slide 61 · Case 5 — similar peripheral atrophy, different context

Illustrative teaching vignette

1. Muscle biopsy shows perifascicular atrophy.

2. The patient has a heliotrope eruption and Gottron papules.

3. The clinical picture does not provide an antisynthetase antibody.

Interpretation

Why should the muscle finding not be called ASS by itself?

Perifascicular atrophy also occurs in dermatomyositis; Clinical and serologic discrimination is necessary.

Vignette is illustrative; No individual patient or result is represented.

Slide 62 · Comparison of the four main phenotypes

Category

Antisynthetase

Dermatomyositis

IMNM

SIBM

Hallmark

Anti-synthetase antibody

DM clinical / antibody pattern

High CK + necrosis

Slow later-life course

Systemic clue

ILD + arthritis

Heliotrope / Gottron

Others uncommon

Dysphagia may occur

Muscle pattern

Perifascicular or scattered

Perifascicular atrophy

Prominent necrosis

Protein aggregates

Comparative summary of the textbook’s principal differentiating features.

Slide 63 · Interpretive limits of the assigned textbook passage

The excerpt gives a syndrome definition, major manifestations and biopsy patterns; It does not give validated diagnostic criteria.

It does not provide sensitivities, prevalence of individual antibodies, ILD subtypes, or therapeutic protocols.

The pathway from antisynthetase antibody to tissue injury is not established in the excerpt.

Biopsy schematics in this lecture are educational illustrations, not authentic clinical specimens.

Slide 64 · Four anchors for diagnostic recall

Antibody

Anti–aminoacyl-tRNA synthetase (often anti-Jo-1).

Phenotype

Myositis + ILD + arthritis; Other skin/vascular clues.

Biopsy

Perifascicular atrophy/necrosis or scattered necrosis.

Pitfall

The perifascicular pattern may resemble dermatomyositis.

Slide 65 · Primary reference and scope

Primary textbook

Robbins, Cotran & Kumar: Pathologic Basis of Disease. 11th edition (2026).

Relevant sections: inflammatory myopathies; antisynthetase syndrome; dermatomyositis; immune-mediated necrotizing myopathy; sporadic inclusion body myositis; myopathic changes.